Author

Madeleine Moore

Cancer Research UK Scotland InstitutePrimary ORCID profile (0009-0003-5246-3955 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Madeleine MooreiD2 papers · Cancer Research UK Scotland Institute

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:imaging· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

Anthony G. Hope· 1 shared Bethany K. HughesiD· 1 shared Björn KruspigiD· 1 shared Charlotte GreeniD· 1 shared Claire J. MackenzieiD· 1 shared Cleo L. BishopiD· 1 shared Colin S. WoodiD· 1 shared Daniel L. Murphy· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anthony G. Hope

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SAMP-Score: A morphology-based machine learning classification method for screening pro-senescence compounds in p16 positive cancer cells

Ryan Wallis, Bethany K. Hughes, Madeleine Moore, Emily A. O’Sullivan, Luke C. McIlvenna, Luke Gammon, Anthony G. Hope, Fiona Bellany, Parul Dixit, Claire J. Mackenzie, Charlotte Green, David W. Gray, Cleo L. Bishop

SAMP-Score identifies pro-senescence compounds in Sen-Mark+ cancers by classifying senescence based on morphology, leading to the discovery of QM5928.

Aging · Oct 30, 2025Peer-reviewedCancer Biology

Increased mRNA translation delays lung adenocarcinoma initiation and exposes a therapeutic vulnerability to MEK inhibitors

Luis Pardo, Madeleine Moore, Ruhi S. Deshmukh, Ian R. Powley, Joseph A. Waldron, Björn Kruspig, Lynn McGarry, Colin S. Wood, Holly Leslie, Mark M. Hughes, Emanuel Jeldes, June Munro, Louise E. Mitchell, Leah Officer-Jones, Rachel L. Pennie, , Jim C. Norman

This study shows that increased mRNA translation delays lung adenocarcinoma initiation and creates a vulnerability to MEK inhibitors in KRAS-driven tumors.

bioRxiv · Mar 19, 2025 · PreprintCancer Biology